Drug Trial Radar · NCT00235508
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Jun 2005
Primary completion
Apr 2006
Study completion Apr 2006
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
Conditions
- Insomnia
- Generalized Anxiety Disorder
Interventions
Eszopiclone (Lunesta)Drug
Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change from baseline in subjective sleep latency averaged over the double-blind treatment period.Time frame: 8 weeks
Locations
64 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mesa, Arizona
Site not named
Scottsdale, Arizona
Site not named
Irvine, California
Site not named
La Mesa, California
Site not named
National City, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
Pasadena, California
Site not named
Redlands, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
Farmington, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Coral Springs, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Orlando, Florida
Site not named
Pembroke Pines, Florida
Site not named
St. Petersburg, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Smyrna, Georgia
Site not named
Northfield, Illinois
Site not named
Indianapolis, Indiana
Site not named
Owensboro, Kentucky
Site not named
Baltimore, Maryland
Site not named
Rockville, Maryland
Site not named
Braintree, Massachusetts
Site not named
Brighton, Massachusetts
Site not named
Brockton, Massachusetts
Site not named
Cambridge, Massachusetts
Site not named
Watertown, Massachusetts
Site not named
St Louis, Missouri
Site not named
Kenilworth, New Jersey
Site not named
Piscataway, New Jersey
Site not named
Brooklyn, New York
Site not named
Lawrence, New York
Site not named
New York, New York
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.